NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Fair Value - Fair Value Measurements (Details)	3 Months Ended		6 Months Ended		12 Months Ended
Fair Value - Fair Value Measurements (Details)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)
Liabilities
Warrants, Fair Value			$ 0		$ 0
Change in fair value of warrant liabilities	$ 0	$ 90,597	$ 0	$ 720,709
Level 3 \| Remaining contractual term (years) \| Estimate of Fair Value Measurement [Member]
Liabilities
Warrants and Rights Outstanding, Measurement Input	0.0		0.0
Level 3 \| Remaining contractual term (years) \| Minimum \| Estimate of Fair Value Measurement [Member]
Liabilities
Warrants and Rights Outstanding, Measurement Input					0.2
Level 3 \| Remaining contractual term (years) \| Maximum \| Estimate of Fair Value Measurement [Member]
Liabilities
Warrants and Rights Outstanding, Measurement Input					0.5
Level 3 \| Common stock price volatility \| Estimate of Fair Value Measurement [Member]
Liabilities
Warrants and Rights Outstanding, Measurement Input	66.4		66.4
Level 3 \| Common stock price volatility \| Minimum \| Estimate of Fair Value Measurement [Member]
Liabilities
Warrants and Rights Outstanding, Measurement Input					60.6
Level 3 \| Common stock price volatility \| Maximum \| Estimate of Fair Value Measurement [Member]
Liabilities
Warrants and Rights Outstanding, Measurement Input					62.5
Level 3 \| Risk-free interest rate \| Estimate of Fair Value Measurement [Member]
Liabilities
Warrants and Rights Outstanding, Measurement Input	0.2		0.2		0.04